ClinicalTrials.gg
CompletedNCT03160521PRISMA-3Updated Feb 22, 2022Results posted

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

A Phase 3 interventional study of Risperidone ISM 75 mg and Risperidone ISM 100 mg in Acute Schizophrenia, sponsored by Rovi Pharmaceuticals Laboratories. Completed at 31 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-02-22.

Sponsored by Rovi Pharmaceuticals Laboratories · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
13th of 123
438 · median 100
Started
2017
with 2 others
Phase 3
34 of 127
2 open now
Registered
107th of 127
by date
Lead sponsor
5 of 127
Rovi Pharmaceuticals Laboratories

Among the 127 studies testing risperidone in Schizophrenia, this one is the 13th largest by enrollment of the 123 interventional ones that give a count, is one of 3 that started in 2017, is one of 34 in phase 3, and was the 107th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of intramuscular (IM) injections of Risperidone ISM® (75 or 100 mg) or placebo, in patients with acute exacerbation of schizophrenia.

Read the detailed description

The study design includes a screening period, a 12-week treatment period, and a follow-up period. Eligible patients will be randomly assigned, under double-blind conditions, to receive the following study drug treatments in a 1:1:1 ratio during the double-blind treatment period: Risperidone ISM® 75 mg, Risperidone ISM® 100 mg, or placebo. The IM study drug (double-blind active Risperidone ISM® or placebo) will be administered in a deltoid or gluteal muscle for a total of 3 times, once every 4 weeks, during the 12-week treatment period.

If indicated for an individual patient, prohibited medications may be washed out during the screening period. Patients who have never taken Risperidone must have a brief trial of oral Risperidone in order to ensure a lack of any clinically significant hypersensitivity reactions before the first dose of the study drug is administered.

Efficacy will be assessed by describing changes in scores on standard psychiatric assessment tools at each visit. Safety assessments will also be conducted at each visit.

The primary objective of this study is the following:

  • To evaluate the efficacy of Risperidone ISM as compared with that of placebo in the treatment of patients with acute exacerbation of schizophrenia

The secondary objectives of this study are the following:

  • To characterize safety and tolerability of Risperidone ISM as compared with that of placebo in patients with acute exacerbation of schizophrenia
  • To quantify healthcare resource utilization (HRU), health-related quality of life (HRQL), and social functioning in patients treated with Risperidone ISM versus placebo for an acute exacerbation of schizophrenia
  • To explore pharmacokinetic characteristics of Risperidone ISM and associations with efficacy

Patients who complete planned double-blind study drug treatments and study evaluations may be eligible to participate in an optional long-term extension segment of the study in which treatment with open-label Risperidone ISM 75 or 100 mg (randomly assigned) would begin immediately; for patients who do not participate in the extension segment, a safety follow-up phone contact will occur after the end-of-treatment visit.

In addition to patients continuing from the double-blind segment of the study (rollover patients), patients not previously enrolled in the study (de novo patients) may be eligible to enter the long-term extension segment of the study. These patients will be evaluated for eligibility at a screening visit and, if eligible, will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 weeks for approximately 12 months.

03

Conditions studied

  • Acute Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for enrolment into the study, each patient must meet all of the following criteria at screening:

  1. Capable of providing

    1. A signed informed consent form must be provided before any study assessments are performed
    2. Patients must be fluent in the language that is spoken by the investigator and the study site staff (including raters) and must be able to read and understand the words in which the informed consent is written
  2. Age ≥ 18 and ≤ 65 years
  3. 18.5 to 40.0 kg/m2 (inclusive)
  4. Current diagnosis of schizophrenia, according to the , Fifth Edition (DSM-5) criteria

    1. Currently experiencing an acute exacerbation or relapse with onset \< 2 months before screening
    2. If inpatient at screening, has been hospitalized for \< 2 weeks for the current exacerbation
    3. ≥ 2 years have elapsed since initial onset of active-phase schizophrenia symptoms
  5. Has been able to achieve outpatient status for > 4 months during the past year
  6. Has previously had a beneficial response (improvement in schizophrenia symptoms), as determined by the investigator, to treatment with an antipsychotic medication other than clozapine
  7. Agrees to discontinue prohibited medications as applicable and as clinically indicated according to investigator instructions
  8. Dosages of all permitted medications are considered to have been stable (with the exception of medication to be used on an as-needed basis) for ≥ 2 weeks prior to the baseline visit and to remain stable during participation in this study
  9. Positive and Negative Syndrome Scale (PANSS) results at the screening and baseline visits meets the following criteria:

    a. Total score between 80 and 120, inclusive b. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale items: i. Item 1 (P1: delusions) ii. Item 2 (P2: conceptual disorganization) iii. Item 3 (P3: hallucinatory behavior) iv. Item 6 (P6: suspiciousness/persecution)

  10. Clinical Global Impression - Severity (CGI-S) score of ≥ 4 (moderately ill or worse)
  11. Resides in a stable living situation and is anticipated to return to that same stable living situation after discharge from the inpatient study unit, in the opinion of the investigator
  12. Has an identified reliable informant who is anticipated to remain the same after the patient is discharged from the inpatient study unit, in the opinion of the investigator
  13. Meets the following criteria:

    a. If a sexually active, is using a medically accepted method, and will continue to use such throughout participation in this study (and for ≥ 6 months after the last dose of IM study drug has been administered); acceptable methods include the following: i. Condoms (male or female) with or without a spermicidal agent ii. Diaphragm or cervical cap with spermicide iii. Intrauterine device iv. Hormonal contraceptive b. If not currently sexually active, them meets the following criteria: i. Agrees that if sexually activity resumes while participating in this study, a medically accepted contraception method will be used

  14. Willing and able to be confined to an inpatient study unit for up to 2 weeks (or longer if clinically indicated), as applicable and as clinically indicated according to investigator instructions
  15. Agrees not to post any personal medical data related to the study or information related to the study on any website or social media site (eg, Facebook, Twitter, and others) during the study duration

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria at screening will not be permitted to enroll in the study:

  1. History of proven inadequate clinical response to treatment with therapeutic doses (with good compliance) of risperidone or paliperidone
  2. History of treatment resistance, defined as failure to respond to 2 discrete adequate trials (≥ 4 weeks with an adequate dose) of 2 different antipsychotic medications; history of clozapine use (exception: use was not because of treatment resistance or psychotic symptoms)
  3. Improvement in PANSS total score 20% or greater between the initial screening visit and first injection
  4. Known or suspected intolerance of or allergy or to risperidone, paliperidone, or any of the in the IM formulations of these
  5. History of neuroleptic malignant syndrome, tardive dyskinesia, or tardive dystonia
  6. History of any other medical condition that is considered to pose any unjustifiable risk or interfere with study assessments
  7. Clinically significant extrapyramidal symptoms at screening or baseline
  8. Answer of "yes" on item 4 or on item 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) (ideation) with the most recent episode occurring within the past 2 months, or answer "yes" to any of the 5 items (behavior) with an episode occurring within the last year
  9. Current diagnosis or a history of substance use disorder according to criteria within 6 months prior to the screening visit (with the exception of tobacco, mild cannabis, or mild alcohol use disorder) or a positive drug screen test (with the exception of cannabis) verified by repeat testing
  10. Lifetime history of diagnosis of schizoaffective disorder or bipolar disorder
  11. Clinically significant comorbid neuropsychiatric disorders including any of the following:

    1. Current untreated or unstable major depressive disorder
    2. Clinically significant cognitive difficulties including dementia, delirium, or amnesic syndrome, within the past 2 years and would interfere with participation in the study
    3. Any other psychiatric condition that would, in the judgment of the investigator, interfere with participation in the study
  12. Clinically significant or unstable medical illness/condition/disorder that would be anticipated, in the investigator's opinion, to potentially compromise patient safety or adversely affect the evaluation of efficacy, including (but not necessarily limited to) the following:

    1. Clinically significant hypotension or hypertension not stabilized by medical therapy (diastolic blood pressure > 105 mmHg)
    2. Unstable thyroid dysfunction in the past 6 months
    3. Malignant tumor within the last 5 years
    4. Neurologic conditions including the following:

    i. History of seizure disorder or condition associated with seizures ii. History of brain tumor, subdural hematoma, or other clinically significant neurological condition within the past 12 months iii. Head trauma with loss of consciousness within 12 months before screening iv. Active acute or chronic central nervous system infection v. Stroke within 6 months before screening e. Cardiac conditions including the following: i. Clinically significant cardiac arrhythmia, cardiomyopathy, or cardiac conduction defect ii. History of myocardial infarction or unstable angina within the last 3 months before screening, or clinically significant abnormality on screening or baseline (ECG) including but not limited to the following: corrected for heart rate using Fridericia's formula (QTcF) > 465 msec if male or > 485 msec if female

  13. Laboratory abnormality that, in the opinion of the investigator, would compromise the well-being of the patient, or any of the following laboratory abnormalities at screening or baseline:

    1. or alanine aminotransferase value ≥ 2 times the upper limit of the laboratory normal reference range
    2. > 9%
    3. ≤ 1.5 × 103 μL
    4. count ≤ 75 × 103 μL
    5. \< 60 mL/min
    6. Positive test result for , surface antigen, or antihepatitis C virus antibody
    7. Positive pregnancy test result
    8. Urine drug screen at screening or baseline shows a positive result for any of the tested substances (potential exceptions: results positive for benzodiazepine may not be exclusionary if the investigator confirms that such medication was medically indicated and consults the medical monitor before enrolling a patient with such a finding; results positive for Tetrahydrocannabinol (THC) may not be exclusionary in certain cases only if exclusion criterion 9 is not met and only if the medical monitor provides approval)
  14. Pregnant, lactating, or breastfeeding
  15. Inadequate gluteal or deltoid musculature or excessive fat, as determined by the investigator, that would interfere with IM study drug injections
  16. Any for IM injections
  17. Receipt of any long-acting antipsychotic medication by IM injection within 60 days before screening
  18. Current involuntary hospitalization or incarceration
  19. Hospitalized for more than 30 days during the 90 days before screening
  20. Participation in another clinical study in which the patient received an experimental or drug or agent within 6 months before screening
  21. Participation in a clinical study with Risperidone ISM within 1 year before screening
  22. Study site personnel and/or persons employed by the investigator or study site or is an immediate family member of such persons
  23. Patients taking any prohibited concomitant medication (see Section 3.2.2.1.1) at the time of randomization visit
  24. Clinically significant ocular disease or visual impairment interfering with the planned ophthalmological examinations or that in the investigator's opinion could potentially compromise patients' ocular safety
  25. Patients with planned or anticipated need for ocular surgery during the treatment period of the trial
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
438 participants (actual)

Study arms

  • Experimental
    Risperidone ISM 75 mg

    Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.

    Drug: Risperidone ISM 75 mg

  • Experimental
    Risperidone ISM 100 mg

    Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.

    Drug: Risperidone ISM 100 mg

  • Placebo comparator
    Placebo

    Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.

    Drug: Placebo of Risperidone ISM

Interventions

  • DrugRisperidone ISM 75 mg

    Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.

    Also known as: Risperidone ISM

  • Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.

    Also known as: Risperidone ISM

  • DrugPlacebo of Risperidone ISM

    Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.

    Also known as: PLACEBO

06

What researchers measure

Primary outcomes

  1. PANSS Total Score Mean Change From Baseline to Endpoint

    The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms whereas higher scores mean a worse outcome. Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

    Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)

Secondary outcomes

  1. CGI-S Total Score Mean Change From Baseline to Endpoint

    The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome. Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

    Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)

  2. CGI-I Score Mean at Endpoint

    The Clinical Global Impression - Improvement (CGI-I) Score consists of a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment. Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse. Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.

    Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)

  3. Overall Response Rate at Endpoint

    Overall response was defined as either PANSS total score ≥ 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

    Time frame: Day 85 or the last post-baseline assessment

  4. PANSS Response Rate at Endpoint

    The definition of Positive and Negative Syndrome Scale (PANSS) response was a decrease from baseline in PANSS total score of ≥ 30% (improvement of symptoms). Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.

    Time frame: Day 85 or the last post-baseline assessment

  5. PANSS Positive Subscale Mean Change From Baseline to Endpoint

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

    Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)

  6. PANSS Negative Subscale Mean Change From Baseline to Endpoint

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

    Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)

  7. PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

    Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)

Other outcomes

  1. PSP Total Score From Baseline at Each Post-baseline Assessment Time Point

    Personal and Social Performance Scale (PSP) total score mean change from baseline at each post-baseline assessment time point. The PSP is a 100-point single-item rating scale that is based on 4 domains: family and social functioning, self-care, work and socially useful activities, and disturbing and aggressive behaviors. Each domain is rated in 6 degrees of severity (absent, mild, manifest, marked, severe, very severe). On the PSP scale, higher scores indicate better social functioning: 71-100 indicates mild to no functional impairment; 31-70 varying degrees of disability and 1-30, minimal functioning needing intense support and/or supervision. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

    Time frame: Day 1 (Baseline), Days 29, 57 and 85 (or the last post-baseline assessment)

  2. SWN-20 Total Score From Baseline at Each Post-baseline Assessment Time Point

    20-item Subjective Well-Being Under Neuroleptics Treatment Scale (SWN-20) total score mean change from baseline at each post-baseline assessment time point. The SWN is a 38-item instrument to measure subjective effects of neuroleptic medications in patients with schizophrenia and consists of 20 positive statements and 18 negative statements. The short form of the SWN, the 20-item SWN-20, was developed in order to allow for quick assessment of subjective side effects in a clinical setting. Like in the original SWN, with the SWN-20 the patient is asked to rate well-being items that have been identified as related to antipsychotic treatment on a 6-point scale ranging from "Not at all" to "Very much." The SWN-20 is scored on a scale ranging from 20 to 120, with higher scores indicating better health-related quality of life (HRQL). The SWN-20 contains five 4-item subscales: mental functioning, self-control, emotional regulation, physical functioning, and social integration. Eac

    Time frame: Day 1 (Baseline), Days 29, 57 and 85 or the last post-baseline assessment

  3. Plasma PK Parameters

    Plasma PK Parameters of Risperidone Active Moiety Cmax values are estimated and based on the plasma level of Day 3 for each dosing Interval; Cmin are the trough levels of Day 29, which is at the end of each dosing Interval;

    Time frame: Day 3 and Day 29 after Dose 1, 2 and 3

07

Results

Posted Feb 4, 2022

Participant flow

Participant flow — Overall Study
MilestoneRisperidone in Situ Microparticle (ISM) 75 mgRisperidone ISM 100 mgPlacebo
Started144146147
Completed1079588
Not completed375159

Outcome measures

PrimaryPANSS Total Score Mean Change From Baseline to Endpoint

The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms whereas higher scores mean a worse outcome. Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

Time frame:
Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Reported as:
Mean · units on a scale
PANSS Total Score Mean Change From Baseline to Endpoint
units on a scaleRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
PANSS Total Score Mean Change From Baseline to Endpoint-24.6 ± 1.51-24.7 ± 1.54-11.0 ± 1.56
SecondaryCGI-S Total Score Mean Change From Baseline to Endpoint

The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome. Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

Time frame:
Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Reported as:
Mean · units on a scale
CGI-S Total Score Mean Change From Baseline to Endpoint
units on a scaleRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
CGI-S Total Score Mean Change From Baseline to Endpoint-1.3 ± 0.09-1.3 ± 0.09-0.6 ± 0.09
SecondaryCGI-I Score Mean at Endpoint

The Clinical Global Impression - Improvement (CGI-I) Score consists of a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment. Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse. Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.

Time frame:
Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Reported as:
Mean · units on a scale
CGI-I Score Mean at Endpoint
units on a scaleRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
CGI-I Score Mean at Endpoint2.5 ± 0.102.5 ± 0.103.3 ± 0.10
SecondaryOverall Response Rate at Endpoint

Overall response was defined as either PANSS total score ≥ 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

Time frame:
Day 85 or the last post-baseline assessment
Reported as:
Number · percentage of participants
Overall Response Rate at Endpoint
percentage of participantsRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
Overall Response Rate at Endpoint59.7 (50.7 to 68.2)54.3 (45.3 to 63.1)20.5 (13.9 to 28.3)
SecondaryPANSS Response Rate at Endpoint

The definition of Positive and Negative Syndrome Scale (PANSS) response was a decrease from baseline in PANSS total score of ≥ 30% (improvement of symptoms). Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.

Time frame:
Day 85 or the last post-baseline assessment
Reported as:
Number · percentage of participants
PANSS Response Rate at Endpoint
percentage of participantsRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
PANSS Response Rate at Endpoint41.9 (33.2 to 50.9)34.9 (26.7 to 43.8)9.1 (4.8 to 15.3)
SecondaryPANSS Positive Subscale Mean Change From Baseline to Endpoint

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

Time frame:
Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Reported as:
Mean · units on a scale
PANSS Positive Subscale Mean Change From Baseline to Endpoint
units on a scaleRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
PANSS Positive Subscale Mean Change From Baseline to Endpoint-8.0 ± 0.49-8.7 ± 0.50-4.1 ± 0.50
SecondaryPANSS Negative Subscale Mean Change From Baseline to Endpoint

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

Time frame:
Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Reported as:
Mean · units on a scale
PANSS Negative Subscale Mean Change From Baseline to Endpoint
units on a scaleRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
PANSS Negative Subscale Mean Change From Baseline to Endpoint-3.8 ± 0.38-3.7 ± 0.39-1.7 ± 0.40
SecondaryPANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.

Time frame:
Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Reported as:
Mean · units on a scale
PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint
units on a scaleRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint-12.8 ± 0.79-12.4 ± 0.81-5.6 ± 0.82
Other pre-specifiedPSP Total Score From Baseline at Each Post-baseline Assessment Time Point

Personal and Social Performance Scale (PSP) total score mean change from baseline at each post-baseline assessment time point. The PSP is a 100-point single-item rating scale that is based on 4 domains: family and social functioning, self-care, work and socially useful activities, and disturbing and aggressive behaviors. Each domain is rated in 6 degrees of severity (absent, mild, manifest, marked, severe, very severe). On the PSP scale, higher scores indicate better social functioning: 71-100 indicates mild to no functional impairment; 31-70 varying degrees of disability and 1-30, minimal functioning needing intense support and/or supervision. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

Time frame:
Day 1 (Baseline), Days 29, 57 and 85 (or the last post-baseline assessment)
Reported as:
Mean · score on a scale
PSP Total Score From Baseline at Each Post-baseline Assessment Time Point
score on a scaleRisperidone ISMPlacebo
Baseline49.93 (49 to 51)50.46 (49 to 52)
Study Day 2959.03 (58 to 60)55.37 (54 to 57)
Study Day 5761.33 (60 to 63)57.07 (55 to 59)
Study Day 8560.60 (59 to 62)54.54 (53 to 56)
Other pre-specifiedSWN-20 Total Score From Baseline at Each Post-baseline Assessment Time Point

20-item Subjective Well-Being Under Neuroleptics Treatment Scale (SWN-20) total score mean change from baseline at each post-baseline assessment time point. The SWN is a 38-item instrument to measure subjective effects of neuroleptic medications in patients with schizophrenia and consists of 20 positive statements and 18 negative statements. The short form of the SWN, the 20-item SWN-20, was developed in order to allow for quick assessment of subjective side effects in a clinical setting. Like in the original SWN, with the SWN-20 the patient is asked to rate well-being items that have been identified as related to antipsychotic treatment on a 6-point scale ranging from "Not at all" to "Very much." The SWN-20 is scored on a scale ranging from 20 to 120, with higher scores indicating better health-related quality of life (HRQL). The SWN-20 contains five 4-item subscales: mental functioning, self-control, emotional regulation, physical functioning, and social integration. Eac

Time frame:
Day 1 (Baseline), Days 29, 57 and 85 or the last post-baseline assessment
Reported as:
Mean · score on a scale
SWN-20 Total Score From Baseline at Each Post-baseline Assessment Time Point
score on a scaleRisperidone ISMPlacebo
Baseline80.86 (79 to 83)80.28 (78 to 83)
Day 2986.90 (85 to 89)83.23 (81 to 86)
Day 5788.26 (87 to 90)86.32 (83 to 89)
Day 8589.14 (88 to 91)85.50 (83 to 88)
Other pre-specifiedPlasma PK Parameters

Plasma PK Parameters of Risperidone Active Moiety Cmax values are estimated and based on the plasma level of Day 3 for each dosing Interval; Cmin are the trough levels of Day 29, which is at the end of each dosing Interval;

Time frame:
Day 3 and Day 29 after Dose 1, 2 and 3
Reported as:
Mean · ng/mL
Plasma PK Parameters
ng/mLRisperidone ISM 75 mgRisperidone ISM 100 mg
Dose 1/Estimated Cmax/Day 327.61 ± 19.99232.00 ± 16.802
Dose 1/Estimated Cmin/Day 2919.21 ± 13.07626.71 ± 14.960
Dose 2/Estimated Cmax/Day 338.95 ± 22.38153.44 ± 23.840
Dose 2/Estimated Cmin/Day 2917.46 ± 13.41827.23 ± 14.070
Dose 3/Estimated Cmax/Day 337.16 ± 19.50450.09 ± 22.242
Dose 3/Estimated Cmin/Day 2920.16 ± 16.84726.14 ± 16.343

Adverse events

Collected over Adverse event data were collected in all visits of the study, from the patient's signature of informed consent form through the end of study for each subject: Screening visit, Baseline (Day 1), Day 3, 4, 8, 15, 22, 29, 31, 43, 57, 59, 71, 85 and follow-up visit (Day 99).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risperidone ISM 75 mg0/144 (0%)2/144 (1.4%)101/144 (70.1%)
Risperidone ISM 100 mg0/146 (0%)5/146 (3.4%)119/146 (81.5%)
Placebo0/147 (0%)5/147 (3.4%)48/147 (32.7%)
Most frequent serious events
Most frequent serious events
EventRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
SchizophreniaPsychiatric disorders1/1442/1464/147
AppendicitisInfections and infestations1/1440/1460/147
Skin infectionInfections and infestations0/1441/1460/147
FallInjury, poisoning and procedural complications0/1441/1460/147
Humerus fractureInjury, poisoning and procedural complications0/1441/1460/147
AgitationPsychiatric disorders0/1441/1460/147
Lower gastrointestinal haemorrhageGastrointestinal disorders0/1440/1461/147
PneumoniaInfections and infestations0/1440/1461/147
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRisperidone ISM 75 mgRisperidone ISM 100 mgPlacebo
Blood prolactin increasedInvestigations13/14421/1460/147
HeadacheNervous system disorders15/14412/1465/147
HyperprolactinaemiaEndocrine disorders8/14413/1461/147
AkathisiaNervous system disorders6/14411/1463/147
Weight increasedInvestigations10/1448/1463/147
Injection site painGeneral disorders8/1444/1465/147
SomnolenceNervous system disorders4/1448/1464/147
SchizophreniaPsychiatric disorders3/1443/1468/147
Alanine aminotransferase increasedInvestigations4/1447/1463/147
DizzinessNervous system disorders5/1446/1464/147

Baseline characteristics

The efficacy analysis was performed on the mITT population containing all randomized patients who received ≥1 dose of study drug with a baseline measurement and ≥1 post-baseline evaluation for the PANSS, and for whom blinding was not potentially compromised owing to a one-off error in the interactive web response system (IWRS) used for randomized treatment assignment.

Age, Continuous
Age, Continuous(years)Risperidone ISM 75 mgRisperidone ISM 100 mgPlaceboTotal
Mean42.6 ± 10.6342.6 ± 11.1440.0 ± 11.3541.7 ± 11.08
Sex: Female, Male
Sex: Female, Male(Participants)Risperidone ISM 75 mgRisperidone ISM 100 mgPlaceboTotal
Female414547133
Male888485257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Risperidone ISM 75 mgRisperidone ISM 100 mgPlaceboTotal
Hispanic or Latino631019
Not Hispanic or Latino123126122371
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Risperidone ISM 75 mgRisperidone ISM 100 mgPlaceboTotal
American Indian or Alaska Native0000
Asian1113
Native Hawaiian or Other Pacific Islander0000
Black or African American586359180
White696571205
More than one race0000
Unknown or Not Reported1012
Region of Enrollment
Region of Enrollment(participants)Risperidone ISM 75 mgRisperidone ISM 100 mgPlaceboTotal
United States727276220
Ukraine575756170
Body Mass Index (BMI)
Body Mass Index (BMI)(Kg/m^2)Risperidone ISM 75 mgRisperidone ISM 100 mgPlaceboTotal
Mean27.77 ± 5.22628.26 ± 5.26828.19 ± 4.71528.07 ± 5.065
Years since Schizophrenia Diagnosis
Years since Schizophrenia Diagnosis(years)Risperidone ISM 75 mgRisperidone ISM 100 mgPlaceboTotal
Mean16.1 ± 10.6715.7 ± 10.4314.3 ± 9.7415.4 ± 10.29
Time since Acute Exacerbation or relapse (weeks)
Time since Acute Exacerbation or relapse (weeks)(days)Risperidone ISM 75 mgRisperidone ISM 100 mgPlaceboTotal
Mean3 ± 1.953 ± 3.673 ± 1.653 ± 2.55
08

Study locations

31 sites
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • CIMU Bellflower
    Cerritos, California 90703, United States
  • Collaborative Neuroscience Network, LLC.
    Garden Grove, California 92845, United States
  • Synergy Research San Diego
    Lemon Grove, California 91945, United States
  • Apostle Clinical Trials
    Long Beach, California 90813, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • CNRI-Los Angeles LLC
    Pico Rivera, California 90660, United States
  • CNRI-San Diego
    San Diego, California 92112, United States
  • Galiz Research
    Hialeah, Florida 33016, United States
  • Innovative Clinical Research Inc.
    Hollywood, Florida 33021, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • CBH Health LLC
    Gaithersburg, Maryland 20877, United States
  • Precise Research Centers MS
    Flowood, Mississippi 39232, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Carolina Clinical Triasl Inc
    Charleston, South Carolina 29407, United States
  • Community Clinical Research Inc.
    Austin, Texas 78754, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Pillar Clinical Research LLC
    Richardson, Texas 75080, United States
  • Regional Clinical Hospital n.a I.I. Mechnicov
    Dnipro, 49005, Ukraine
  • Kharkiv Regional Clinical Psychiatric Hospital
    Kharkiv, 61068, Ukraine
  • Public Healthcare Institution "Kharkiv Regional Clinical Psychiatric Hospital No. 3", Center of Urgent Psychiatry
    Kharkiv, 61068, Ukraine
  • Kherson Regional Psychiatric Hospital
    Kherson, 73488, Ukraine
  • Kiev City Psychiatric Hospital No. 2
    Kiev, 02192, Ukraine
  • Kyiv Regional Medical Association "Psykhiatriya" in Kyiv
    Kiev, 04080, Ukraine
  • CI Lviv Regional Clinical Psychiatric Hospital. Department 20
    Lviv, 79021, Ukraine
  • CI Lviv Regional Clinical Psychiatric Hospital. Department 25
    Lviv, 79021, Ukraine
  • Odesa Regional Medical Centre of Mental Health
    Odesa, 65006, Ukraine
  • Maltsev Regional Clinical Psychiatric Ho
    Poltava, 36013, Ukraine
  • N.I. Pyrogov Vinnytsya Natl Medical University
    Vinnytsia, 21005, Ukraine
09

References and documents

Publications

  • Correll CU, Litman RE, Filts Y, Llaudo J, Naber D, Torres F, Martinez J. Efficacy and safety of once-monthly Risperidone ISM(R) in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020 Nov 25;6(1):37. doi: 10.1038/s41537-020-00127-y. PubMed 33239746 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Dec 2018, 18 months.

Results were first posted in Feb 2022, 3 years 1 month after primary completion. A results delay was requested in Dec 2019.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 18 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2017
First posted
May 19, 2017
StartActual
Jun 2, 2017
Primary completionActual
Dec 17, 2018
CompletionActual
Dec 17, 2018
Results delay requested
Dec 17, 2019
Results first posted
Feb 4, 2022
Last update
Feb 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03160521
Lead sponsor
Rovi Pharmaceuticals Laboratories
Responsible party
Sponsor
First posted
May 19, 2017
Start date
Jun 2, 2017
Primary completion
Dec 17, 2018
Completion
Dec 17, 2018
Results posted
Feb 4, 2022
Last update
Feb 22, 2022

Study contacts

Robert Litman
principal investigator · CBH Health LLC
Yuriy Filts
principal investigator · CI Lviv Regional Clinical Psychiatric Hospital. Department 25

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion